Phase IIIb PERUSE Study of Pertuzumab, Trastuzumab and a Taxane for HER2-Positive Advanced Breast Cancer


Phase IIIb PERUSE Study of Pertuzumab, Trastuzumab and a Taxane for HER2-Positive Advanced Breast Cancer
Slides from a presentation at SABCS 2012 and transcribed comments from a recent interview with Edith A Perez, MD (1/17/13)
Bachelot T et al. A single-arm Phase IIIb study of pertuzumab and trastuzumab with a taxane as first-line therapy for patients with HER2-positive advanced breast cancer (PERUSE). San Antonio Breast Cancer Symposium 2012;Abstract OT1-1-02.

Dr Perez is Deputy Director at Large of the Mayo Clinic Cancer Center, Group Vice Chair of the Alliance of Clinical Trials in Oncology and Serene M and Frances C Durling Professor of Medicine at the Mayo Clinic in Jacksonville, Florida.